Loading…
Is Patient Support Program Participation Associated with Longer Persistence and Improved Adherence Among New Users of Adalimumab? A Retrospective Cohort Study
Introduction Adalimumab (ADA) is a medication used in the treatment of several autoimmune diseases. Despite the beneficial effects of ADA, its adherence and persistence rates are low. Patients treated with ADA from Clalit Health Services (CHS) can enroll in AbbVie’s patient support program (PSP), wh...
Saved in:
| Published in: | Advances in therapy 2018-05, Vol.35 (5), p.655-665 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c344t-e32dd8d277fb2d3381976f97eb6ca4558405ee1b68a757de7f1cf1dcf0b6b1653 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c344t-e32dd8d277fb2d3381976f97eb6ca4558405ee1b68a757de7f1cf1dcf0b6b1653 |
| container_end_page | 665 |
| container_issue | 5 |
| container_start_page | 655 |
| container_title | Advances in therapy |
| container_volume | 35 |
| creator | Srulovici, Einav Garg, Vishvas Ghilai, Adi Feldman, Becca Hoshen, Moshe Balicer, Ran D. Skup, Martha Leventer-Roberts, Maya |
| description | Introduction
Adalimumab (ADA) is a medication used in the treatment of several autoimmune diseases. Despite the beneficial effects of ADA, its adherence and persistence rates are low. Patients treated with ADA from Clalit Health Services (CHS) can enroll in AbbVie’s patient support program (PSP), which aims to improve ADA adherence and persistence. Therefore, we examine whether PSP participation is associated with a longer persistence and/or an improved adherence to ADA.
Methods
A real-world retrospective cohort study of all new ADA users from CHS, comparing those enrolled in the offered PSP to those not enrolled. The data regarding PSP users can be tracked using CHS’s data warehouse. The index date was defined as the date of the patients’ first purchase of ADA occurring between August 1, 2012 and December 31, 2014. The follow-up data were collected at 12, 24, and 36 months. Persistence was assessed using survival analyses of time until discontinuation, and adherence was assessed using medication possession ratio (MPR).
Results
There were 1520 patients in the study, 755 (49.7%) of whom were PSP users. PSP users were 54.3% female vs. 51.9% among non-PSP users (
p
= 0.355) and they were significantly younger than non-PSP users (mean age 42.3 vs. 45.0 years,
p
= 0.002) The PSP and non-PSP users’ persistence was 673 and 574 days, respectively (
p |
| doi_str_mv | 10.1007/s12325-018-0706-0 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2038267684</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2038267684</sourcerecordid><originalsourceid>FETCH-LOGICAL-c344t-e32dd8d277fb2d3381976f97eb6ca4558405ee1b68a757de7f1cf1dcf0b6b1653</originalsourceid><addsrcrecordid>eNp9kc1u3CAUhVHVqpkkfYBuKpbdOAFsA7OqrFF-Rhqlo_xI2SEM1xmisXEBJ8rL5FnLZNIsu0BI93z36MBB6DslJ5QQcRopK1ldECoLIggvyCc0o5LXRT7sM5oRUdGClfL-AB3G-EgII6KWX9EBm4tKzmk1Q6_LiNc6ORgSvpnG0YeE18E_BN3neUjOuDHLfsBNjN44ncDiZ5c2eOWHBwh4DSG6mGAwgPVg8bIfg3_KUGM3EN7GTZ9RfAXP-C5mGvsui3rr-qnX7S_c4GtIwccRTHJPgBd-s0txkyb7coy-dHob4dv7fYTuzs9uF5fF6vfFctGsClNWVSqgZNZKy4ToWmbLUtK54N1cQMuNrupaVqQGoC2XWtTCguio6ag1HWl5S3ldHqGfe98c_s8EManeRQPbrR7AT1ExUkrGBZdVRukeNTlzDNCpMbhehxdFidrVova1qFyL2tWiSN758W4_tT3Yj41_PWSA7YGYpd2_qkc_hSE_-T-ufwEXXZsZ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2038267684</pqid></control><display><type>article</type><title>Is Patient Support Program Participation Associated with Longer Persistence and Improved Adherence Among New Users of Adalimumab? A Retrospective Cohort Study</title><source>Springer Nature</source><creator>Srulovici, Einav ; Garg, Vishvas ; Ghilai, Adi ; Feldman, Becca ; Hoshen, Moshe ; Balicer, Ran D. ; Skup, Martha ; Leventer-Roberts, Maya</creator><creatorcontrib>Srulovici, Einav ; Garg, Vishvas ; Ghilai, Adi ; Feldman, Becca ; Hoshen, Moshe ; Balicer, Ran D. ; Skup, Martha ; Leventer-Roberts, Maya</creatorcontrib><description>Introduction
Adalimumab (ADA) is a medication used in the treatment of several autoimmune diseases. Despite the beneficial effects of ADA, its adherence and persistence rates are low. Patients treated with ADA from Clalit Health Services (CHS) can enroll in AbbVie’s patient support program (PSP), which aims to improve ADA adherence and persistence. Therefore, we examine whether PSP participation is associated with a longer persistence and/or an improved adherence to ADA.
Methods
A real-world retrospective cohort study of all new ADA users from CHS, comparing those enrolled in the offered PSP to those not enrolled. The data regarding PSP users can be tracked using CHS’s data warehouse. The index date was defined as the date of the patients’ first purchase of ADA occurring between August 1, 2012 and December 31, 2014. The follow-up data were collected at 12, 24, and 36 months. Persistence was assessed using survival analyses of time until discontinuation, and adherence was assessed using medication possession ratio (MPR).
Results
There were 1520 patients in the study, 755 (49.7%) of whom were PSP users. PSP users were 54.3% female vs. 51.9% among non-PSP users (
p
= 0.355) and they were significantly younger than non-PSP users (mean age 42.3 vs. 45.0 years,
p
= 0.002) The PSP and non-PSP users’ persistence was 673 and 574 days, respectively (
p
< 0.001). Further, the PSP users were more likely than the non-PSP users to be persistently taking medication at the 12-month follow-up (57.5% vs. 45.6%,
p
< 0.001). The 12-month mean adherence rate among those with at least 12 months of persistence was significantly improved for the PSP users compared to the non-PSP users (94.1% vs. 92.9%,
p
= 0.026).
Conclusion
The AbbVie PSP provided to CHS patients was associated with a longer persistence among new users of ADA. It was also associated with significantly higher adherence rate within the first 12 months.
Funding
AbbVie Inc.</description><identifier>ISSN: 0741-238X</identifier><identifier>EISSN: 1865-8652</identifier><identifier>DOI: 10.1007/s12325-018-0706-0</identifier><identifier>PMID: 29748914</identifier><language>eng</language><publisher>Cheshire: Springer Healthcare</publisher><subject>Cardiology ; Endocrinology ; Health technology assessment ; Internal Medicine ; Medicine ; Medicine & Public Health ; Oncology ; Original Research ; Pharmacology/Toxicology ; Rheumatology</subject><ispartof>Advances in therapy, 2018-05, Vol.35 (5), p.655-665</ispartof><rights>Springer Healthcare Ltd., part of Springer Nature 2018</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c344t-e32dd8d277fb2d3381976f97eb6ca4558405ee1b68a757de7f1cf1dcf0b6b1653</citedby><cites>FETCH-LOGICAL-c344t-e32dd8d277fb2d3381976f97eb6ca4558405ee1b68a757de7f1cf1dcf0b6b1653</cites><orcidid>0000-0003-1291-8284</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29748914$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Srulovici, Einav</creatorcontrib><creatorcontrib>Garg, Vishvas</creatorcontrib><creatorcontrib>Ghilai, Adi</creatorcontrib><creatorcontrib>Feldman, Becca</creatorcontrib><creatorcontrib>Hoshen, Moshe</creatorcontrib><creatorcontrib>Balicer, Ran D.</creatorcontrib><creatorcontrib>Skup, Martha</creatorcontrib><creatorcontrib>Leventer-Roberts, Maya</creatorcontrib><title>Is Patient Support Program Participation Associated with Longer Persistence and Improved Adherence Among New Users of Adalimumab? A Retrospective Cohort Study</title><title>Advances in therapy</title><addtitle>Adv Ther</addtitle><addtitle>Adv Ther</addtitle><description>Introduction
Adalimumab (ADA) is a medication used in the treatment of several autoimmune diseases. Despite the beneficial effects of ADA, its adherence and persistence rates are low. Patients treated with ADA from Clalit Health Services (CHS) can enroll in AbbVie’s patient support program (PSP), which aims to improve ADA adherence and persistence. Therefore, we examine whether PSP participation is associated with a longer persistence and/or an improved adherence to ADA.
Methods
A real-world retrospective cohort study of all new ADA users from CHS, comparing those enrolled in the offered PSP to those not enrolled. The data regarding PSP users can be tracked using CHS’s data warehouse. The index date was defined as the date of the patients’ first purchase of ADA occurring between August 1, 2012 and December 31, 2014. The follow-up data were collected at 12, 24, and 36 months. Persistence was assessed using survival analyses of time until discontinuation, and adherence was assessed using medication possession ratio (MPR).
Results
There were 1520 patients in the study, 755 (49.7%) of whom were PSP users. PSP users were 54.3% female vs. 51.9% among non-PSP users (
p
= 0.355) and they were significantly younger than non-PSP users (mean age 42.3 vs. 45.0 years,
p
= 0.002) The PSP and non-PSP users’ persistence was 673 and 574 days, respectively (
p
< 0.001). Further, the PSP users were more likely than the non-PSP users to be persistently taking medication at the 12-month follow-up (57.5% vs. 45.6%,
p
< 0.001). The 12-month mean adherence rate among those with at least 12 months of persistence was significantly improved for the PSP users compared to the non-PSP users (94.1% vs. 92.9%,
p
= 0.026).
Conclusion
The AbbVie PSP provided to CHS patients was associated with a longer persistence among new users of ADA. It was also associated with significantly higher adherence rate within the first 12 months.
Funding
AbbVie Inc.</description><subject>Cardiology</subject><subject>Endocrinology</subject><subject>Health technology assessment</subject><subject>Internal Medicine</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Oncology</subject><subject>Original Research</subject><subject>Pharmacology/Toxicology</subject><subject>Rheumatology</subject><issn>0741-238X</issn><issn>1865-8652</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp9kc1u3CAUhVHVqpkkfYBuKpbdOAFsA7OqrFF-Rhqlo_xI2SEM1xmisXEBJ8rL5FnLZNIsu0BI93z36MBB6DslJ5QQcRopK1ldECoLIggvyCc0o5LXRT7sM5oRUdGClfL-AB3G-EgII6KWX9EBm4tKzmk1Q6_LiNc6ORgSvpnG0YeE18E_BN3neUjOuDHLfsBNjN44ncDiZ5c2eOWHBwh4DSG6mGAwgPVg8bIfg3_KUGM3EN7GTZ9RfAXP-C5mGvsui3rr-qnX7S_c4GtIwccRTHJPgBd-s0txkyb7coy-dHob4dv7fYTuzs9uF5fF6vfFctGsClNWVSqgZNZKy4ToWmbLUtK54N1cQMuNrupaVqQGoC2XWtTCguio6ag1HWl5S3ldHqGfe98c_s8EManeRQPbrR7AT1ExUkrGBZdVRukeNTlzDNCpMbhehxdFidrVova1qFyL2tWiSN758W4_tT3Yj41_PWSA7YGYpd2_qkc_hSE_-T-ufwEXXZsZ</recordid><startdate>20180501</startdate><enddate>20180501</enddate><creator>Srulovici, Einav</creator><creator>Garg, Vishvas</creator><creator>Ghilai, Adi</creator><creator>Feldman, Becca</creator><creator>Hoshen, Moshe</creator><creator>Balicer, Ran D.</creator><creator>Skup, Martha</creator><creator>Leventer-Roberts, Maya</creator><general>Springer Healthcare</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-1291-8284</orcidid></search><sort><creationdate>20180501</creationdate><title>Is Patient Support Program Participation Associated with Longer Persistence and Improved Adherence Among New Users of Adalimumab? A Retrospective Cohort Study</title><author>Srulovici, Einav ; Garg, Vishvas ; Ghilai, Adi ; Feldman, Becca ; Hoshen, Moshe ; Balicer, Ran D. ; Skup, Martha ; Leventer-Roberts, Maya</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c344t-e32dd8d277fb2d3381976f97eb6ca4558405ee1b68a757de7f1cf1dcf0b6b1653</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Cardiology</topic><topic>Endocrinology</topic><topic>Health technology assessment</topic><topic>Internal Medicine</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Oncology</topic><topic>Original Research</topic><topic>Pharmacology/Toxicology</topic><topic>Rheumatology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Srulovici, Einav</creatorcontrib><creatorcontrib>Garg, Vishvas</creatorcontrib><creatorcontrib>Ghilai, Adi</creatorcontrib><creatorcontrib>Feldman, Becca</creatorcontrib><creatorcontrib>Hoshen, Moshe</creatorcontrib><creatorcontrib>Balicer, Ran D.</creatorcontrib><creatorcontrib>Skup, Martha</creatorcontrib><creatorcontrib>Leventer-Roberts, Maya</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Advances in therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Srulovici, Einav</au><au>Garg, Vishvas</au><au>Ghilai, Adi</au><au>Feldman, Becca</au><au>Hoshen, Moshe</au><au>Balicer, Ran D.</au><au>Skup, Martha</au><au>Leventer-Roberts, Maya</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Is Patient Support Program Participation Associated with Longer Persistence and Improved Adherence Among New Users of Adalimumab? A Retrospective Cohort Study</atitle><jtitle>Advances in therapy</jtitle><stitle>Adv Ther</stitle><addtitle>Adv Ther</addtitle><date>2018-05-01</date><risdate>2018</risdate><volume>35</volume><issue>5</issue><spage>655</spage><epage>665</epage><pages>655-665</pages><issn>0741-238X</issn><eissn>1865-8652</eissn><abstract>Introduction
Adalimumab (ADA) is a medication used in the treatment of several autoimmune diseases. Despite the beneficial effects of ADA, its adherence and persistence rates are low. Patients treated with ADA from Clalit Health Services (CHS) can enroll in AbbVie’s patient support program (PSP), which aims to improve ADA adherence and persistence. Therefore, we examine whether PSP participation is associated with a longer persistence and/or an improved adherence to ADA.
Methods
A real-world retrospective cohort study of all new ADA users from CHS, comparing those enrolled in the offered PSP to those not enrolled. The data regarding PSP users can be tracked using CHS’s data warehouse. The index date was defined as the date of the patients’ first purchase of ADA occurring between August 1, 2012 and December 31, 2014. The follow-up data were collected at 12, 24, and 36 months. Persistence was assessed using survival analyses of time until discontinuation, and adherence was assessed using medication possession ratio (MPR).
Results
There were 1520 patients in the study, 755 (49.7%) of whom were PSP users. PSP users were 54.3% female vs. 51.9% among non-PSP users (
p
= 0.355) and they were significantly younger than non-PSP users (mean age 42.3 vs. 45.0 years,
p
= 0.002) The PSP and non-PSP users’ persistence was 673 and 574 days, respectively (
p
< 0.001). Further, the PSP users were more likely than the non-PSP users to be persistently taking medication at the 12-month follow-up (57.5% vs. 45.6%,
p
< 0.001). The 12-month mean adherence rate among those with at least 12 months of persistence was significantly improved for the PSP users compared to the non-PSP users (94.1% vs. 92.9%,
p
= 0.026).
Conclusion
The AbbVie PSP provided to CHS patients was associated with a longer persistence among new users of ADA. It was also associated with significantly higher adherence rate within the first 12 months.
Funding
AbbVie Inc.</abstract><cop>Cheshire</cop><pub>Springer Healthcare</pub><pmid>29748914</pmid><doi>10.1007/s12325-018-0706-0</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0003-1291-8284</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0741-238X |
| ispartof | Advances in therapy, 2018-05, Vol.35 (5), p.655-665 |
| issn | 0741-238X 1865-8652 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2038267684 |
| source | Springer Nature |
| subjects | Cardiology Endocrinology Health technology assessment Internal Medicine Medicine Medicine & Public Health Oncology Original Research Pharmacology/Toxicology Rheumatology |
| title | Is Patient Support Program Participation Associated with Longer Persistence and Improved Adherence Among New Users of Adalimumab? A Retrospective Cohort Study |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T03%3A30%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Is%20Patient%20Support%20Program%20Participation%20Associated%20with%20Longer%20Persistence%20and%20Improved%20Adherence%20Among%20New%20Users%20of%20Adalimumab?%20A%20Retrospective%20Cohort%20Study&rft.jtitle=Advances%20in%20therapy&rft.au=Srulovici,%20Einav&rft.date=2018-05-01&rft.volume=35&rft.issue=5&rft.spage=655&rft.epage=665&rft.pages=655-665&rft.issn=0741-238X&rft.eissn=1865-8652&rft_id=info:doi/10.1007/s12325-018-0706-0&rft_dat=%3Cproquest_cross%3E2038267684%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c344t-e32dd8d277fb2d3381976f97eb6ca4558405ee1b68a757de7f1cf1dcf0b6b1653%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2038267684&rft_id=info:pmid/29748914&rfr_iscdi=true |